HMG-CoA還元酵素阻害薬の薬剤経済分析 : 冠動脈疾患再発抑制無作為化比較試験を用いた検討 Pharmacoeconomic Analysis of 3-Hydroxy-3-Methylglutaryl Coenzyme : A Reductase Inhibitor Therapy for the Secondary Prevention of Coronary Heart Disease

この論文にアクセスする

この論文をさがす

著者

抄録

Objective: The pharmacoeconomics of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (pravastatin) therapy were evaluated using data from an open-labeled, randomized, controlled trial (PCS: Prevention of Coronary Sclerosis study) with a two-year follow-up period.<br>Methods: Patients with a serum total cholesterol concentration of between 180 and 219mg/dL at baseline were randomly assigned to two groups: the pravastatin group (n=54) and the group that did not receive cholesterol-lowering drugs (no-pravastatin group, n=66). A cost-minimization analysis and a cost-effectiveness analysis were then performed from the perspective of a health insurance company, using insurance information obtained from the subjects. In the cost-minimization analysis, the expected costs associated with percutaneous transluminal coronary angioplasty (PTCA) and the pravastatin prescription were compared; the total medication costs between the two groups were also compared. In the cost-effectiveness analysis, the estimated savings per event-free year were calculated.<br>Results: The median cost of a PTCA procedure was \1, 323, 492. The expected insurance cost for two years was \182, 532 per patient in the pravastatin group and \224, 444 per patient in the no-pravastatin group. The cost-minimization analysis showed that the cost of healthcare for the no-pravastatin group was higher than that for the pravastatin group. The mean total cost of medication was \729, 849 per patient in the pravastatin group and \989, 606 per patient in the no-pravastatin group. The cost-effectiveness ratio for coronary heart disease was \2, 766, 994.<br>Conclusion: Pravastatin therapy in normocholesterolemic patients with coronary sclerosis seems to have an excellent pharmacoeconomic profile.

収録刊行物

  • 日本衞生學雜誌

    日本衞生學雜誌 59(3), 335-341, 2004-07-01

    日本衛生学会

参考文献:  18件中 1-18件 を表示

各種コード

  • NII論文ID(NAID)
    10013332922
  • NII書誌ID(NCID)
    AN00185923
  • 本文言語コード
    JPN
  • 資料種別
    ART
  • ISSN
    00215082
  • NDL 記事登録ID
    7042466
  • NDL 雑誌分類
    ZS17(科学技術--医学--衛生学・公衆衛生)
  • NDL 請求記号
    Z19-194
  • データ提供元
    CJP書誌  NDL  J-STAGE 
ページトップへ